🍪 CompoundTalk uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsClinical Trials & ResearchCagriSema (amylin + semaglutide) — REDEFINE Phase 3 results Page 4

CagriSema (amylin + semaglutide) — REDEFINE Phase 3 results

Dr.Martinez Sun, Jun 7, 2026 at 10:19 AM 20 replies 606 viewsPage 4 of 4
BiostatsBrad
Member
456
2,345
Jul 2024
Durham, NC
Jun 8, 2026 at 7:28 AM#16
Dr.LeslieOBGYN said:
Almost every unanswerable question in these threads is unanswerable because three things changed in the same fortnight, and no amount of subsequent…

This matches mine closely enough to be worth saying so out loud.

Last edited: Jun 8, 2026 at 8:28 AM
23 23LindaRN_retired, tommy_boulder, hyun_seoul and 20 others
Reply Quote Save Share Report
Dr.PeteFamMed
Senior Member
2,012
9,234
Jan 2024
Minneapolis, MN
Jun 8, 2026 at 10:51 AM#17
jason_paloalto said:
One habit that pays for itself: post the method alongside the number.

Same experience, arrived at from the opposite direction. The detail I would add is minor and it is already implied above.

22 22tommy_boulder, hyun_seoul, jim_asheville and 19 others
Reply Quote Save Share Report
NurseLeah_Nash
Member
278
1,234
Sep 2024
Nashville, TN
Jun 8, 2026 at 2:13 PM#18
jason_paloalto said:
One habit that pays for itself: post the method alongside the number.

Adding the part of the answer the thread has not reached. The mechanism that matters here is not stomach emptying, it is central. GLP-1 receptor agonism in the arcuate nucleus stimulates POMC neurons and suppresses AgRP/NPY signalling, which is why the effect is appetite and food salience rather than physical fullness. Delayed gastric emptying largely tachyphylaxes over the first months; the appetite effect does not.

Last edited: Jun 8, 2026 at 3:13 PM
21 21PeptideSynthNJ, Dr.KarenChen, Dr.NateNeph and 18 others
Reply Quote Save Share Report

PeptideMeter — Independent Peptide Analytics

Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.

View Results
bri_stats
Member
789
3,456
May 2024
Seattle, WA
Jun 8, 2026 at 5:36 PM#19

One concrete data point for the thread. Worth knowing that the injection site changes very little. Abdomen, thigh and upper arm are bioequivalent for semaglutide, so a site change is not a plausible explanation for a bad week.

Last edited: Jun 8, 2026 at 9:36 PM
20 20JessicaM_2024, TomFromTexas, mike.trainer_LA and 17 others
Reply Quote Save Share Report
Admin
Administrator
2,456
9,812
Oct 2023
Online
Jun 8, 2026 at 8:59 PM#20

Moderator note: a post naming a supplier has been edited. Discuss suppliers in the review sections, not here. Report rather than reply if it drifts again.

48 23PeptideSynthNJ, Dr.KarenChen, Dr.NateNeph and 45 others
Reply Quote Save Share Report

Similar Threads

FLOW trial: semaglutide renal outcomes — NEJM publication review14 replies
SELECT trial: semaglutide 2.4mg cardiovascular outcomes — 4yr data9 replies
TRIUMPH program (retatrutide) — Phase 3 trial design and endpoints13 replies
Orforglipron ATTAIN trials — oral non-peptide GLP-1 agonist8 replies
Survodutide (GCG/GLP-1) — MASH and obesity trial results16 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register